

Projects Formerly Funded by CARB-X

Sponsor	Product	Novelty			Description	Priority		Development Stage				Stop Date
		New Abx Class	New Non-traditional Product	New Target		CDC	WHO	Hit to Lead	Lead Optimization	Pre-Clinical	Phase I	
Achaogen	AKAO-LpxC	✓		✓	LpxC inhibitor	✓	✓	<i>P. aeruginosa</i>				11/2017
Redx Pharma	NBTI	✓			Dual-acting topoisomerase inhibitor	✓	✓	<i>Acinetobacter + P. aeruginosa + Enterobacteriaceae</i>				11/2017

The above projects are former *Powered by CARB-X* projects that have been closed by the company for a variety of reasons and are no longer funded by CARB-X. The stage of development is approximate as of closure.